JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 2.35 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $211,000 | -3.7% | 4,703 | -36.0% | 0.00% | – |
| Q2 2017 | $219,000 | -43.1% | 7,343 | -57.7% | 0.00% | -100.0% |
| Q1 2017 | $385,000 | -2.3% | 17,365 | -16.9% | 0.00% | 0.0% |
| Q4 2016 | $394,000 | +73.6% | 20,905 | +175.9% | 0.00% | 0.0% |
| Q3 2016 | $227,000 | -2.6% | 7,577 | +24.9% | 0.00% | 0.0% |
| Q2 2016 | $233,000 | -93.0% | 6,068 | -93.0% | 0.00% | -88.9% |
| Q1 2016 | $3,317,000 | -15.1% | 87,089 | -2.0% | 0.01% | 0.0% |
| Q4 2015 | $3,905,000 | +5.4% | 88,830 | -2.5% | 0.01% | 0.0% |
| Q3 2015 | $3,706,000 | -21.4% | 91,070 | +3.0% | 0.01% | -10.0% |
| Q2 2015 | $4,714,000 | – | 88,404 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |